Nurix Therapeutics (NASDAQ:NRIX) Trading Up 4.5%

Nurix Therapeutics, Inc. (NASDAQ:NRIX) shares traded up 4.5% during trading on Monday . The stock traded as high as $26.08 and last traded at $25.92. 47,681 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 897,871 shares. The stock had previously closed at $24.80.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Barclays boosted their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Truist Financial assumed coverage on shares of Nurix Therapeutics in a research note on Wednesday, July 31st. They issued a “buy” rating and a $36.00 price target for the company. Royal Bank of Canada raised their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday, July 12th. Robert W. Baird initiated coverage on Nurix Therapeutics in a research report on Friday, September 6th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $27.00.

Nurix Therapeutics Stock Up 2.6 %

The firm’s 50-day moving average price is $22.60 and its two-hundred day moving average price is $17.93. The firm has a market capitalization of $1.25 billion, a PE ratio of -8.63 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). The business had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. Equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.95 EPS for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the sale, the chief financial officer now owns 31,002 shares in the company, valued at approximately $781,870.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Gwenn Hansen sold 3,408 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $70,443.36. Following the transaction, the insider now owns 45,150 shares of the company’s stock, valued at $933,250.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the completion of the sale, the chief financial officer now owns 31,002 shares of the company’s stock, valued at $781,870.44. The disclosure for this sale can be found here. Insiders have sold a total of 59,815 shares of company stock valued at $1,416,751 in the last 90 days. 7.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Driehaus Capital Management LLC bought a new stake in Nurix Therapeutics in the second quarter worth $26,778,000. Redmile Group LLC increased its holdings in shares of Nurix Therapeutics by 37.7% during the 1st quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after acquiring an additional 1,226,497 shares during the last quarter. Samlyn Capital LLC bought a new position in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $12,177,000. Affinity Asset Advisors LLC lifted its holdings in Nurix Therapeutics by 176.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock worth $7,122,000 after purchasing an additional 440,112 shares during the last quarter. Finally, Ikarian Capital LLC bought a new stake in Nurix Therapeutics during the first quarter worth approximately $4,410,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.